Sleep drug tested to stop Alzheimer's before it starts
NCT ID NCT04629547
First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 3 times
Summary
This study tests whether taking the sleep medication suvorexant (Belsomra) nightly for two years can slow the buildup of amyloid plaques in the brain, a hallmark of Alzheimer's disease. Researchers will enroll 200 healthy adults aged 65 and older with no signs of dementia. The goal is to see if improving sleep can reduce Alzheimer's risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
suvorexant (Belsomra)
What this could lead to
If it works, this could point toward a way to delay or prevent Alzheimer's by improving sleep.
What could go wrong
This is an early phase 2 trial with only 200 participants, so results may not apply to everyone. The drug may not slow brain changes, and sleep aids can have side effects like drowsiness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••